Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 110,331

Document Document Title
WO/2016/044150A1
The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and / or for the treatment and / or pre...  
WO/2016/044386A1
formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by vo...  
WO/2016/041618A1
The present invention relates to substituted indazoles and related heterocycles. These compounds are useful for the prevention and/or treatment of hyperproliferative, inflammatory and degenerative disorders and diseases. Thus, this inven...  
WO/2016/044331A1
Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.  
WO/2016/043996A1
The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE imnhibitor).  
WO/2016/042775A1
Disclosed are compounds useful as inhibitors of phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.  
WO/2016/042194A1
The invention relates to substituted heterocyclic indole derivatives of formula (I), which act as activators of the AMP-activated protein kinase (AMPK) and to the use thereof for the treatment and prevention of diseases or disorders regu...  
WO/2016/041192A1
Disclosed is a use of ligustilide, comprising a use of ligustilide to improve a therapeutic benefit of a stem cell, and a use of ligustilide and a stem cell treated therewith in a stem cell treatment. Treating the stem cell via the ligus...  
WO/2016/044770A1
Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. P...  
WO/2016/044314A1
Disclosed herein are novel drug combinations comprising a glutathione peroxidase (GPx) mimic compound and an antipsychotic agent, pharmaceutical compositions comprising one or more of such combinations, methods of preparing pharmaceutica...  
WO/2016/044131A1
This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutic...  
WO/2016/044447A1
There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorder...  
WO/2016/042453A1
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibiti...  
WO/2016/044299A1
Extracts of plants of the Lamiaceae family, including the Mentha genus, are shown to have a positive impact on overall cognitive health, including improvements in memory, reasoning, attention/concentration, planning, mood, sleep and asso...  
WO/2016/042452A1
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibiti...  
WO/2016/044777A1
Compounds having a structure of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R3c, R4a, R4b, R5, R6, Z and X are as defined herein are provided. Pharmaceutical composit...  
WO/2016/041058A1
The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligome...  
WO/2016/043517A1
The present invention relates to a pharmaceutical composition for treating and preventing degenerative neurological disorders, containing, as an active ingredient, a mixture extract of two or more types selected from the group consisting...  
WO/2016/042089A1
The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the presen...  
WO/2016/043354A1
The present invention relates to a pharmaceutical composition and, more specifically, to a novel pharmaceutical composition, containing osmotin as an active ingredient, for treating Alzheimer's disease.  
WO/2016/037592A1
Disclosed are an aminosulfonyl compound represented by general formula I or a tautomer, enantiomer, racemate or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and a use thereof. The ...  
WO/2016/039339A1
 The purpose of the present invention is to provide a drug that can promote the growth of oligodendrocyte precursor cells, and effectively prevent or treat demyelinating disease. FGF21 acts to promote the growth of oligodendrocyte prec...  
WO/2016/039660A1
The present invention relates to medicine, and more particularly to pharmacology and psychiatry, and can be used in the manufacture of drugs for treating treatment-resistant forms of schizophrenia. To this end, it is proposed to use the ...  
WO/2016/040789A1
The present invention is directed to compounds of Formula (I): Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of usi...  
WO/2016/040358A1
Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, or adverse effects associated with triptan administration.  
WO/2016/039359A1
The present invention relates to: a terpenoid derivative which is capable of activating a Keap1/Nrf2/ARE signaling pathway and has an excellent anti-inflammatory activity and an excellent cell-protecting activity; and a sustained-release...  
WO/2016/039398A1
The present invention relates to a neuroprotective agent and addresses the problem of providing a medicine for preventing and/or treating neurological disease. The problem is solved by using a compound, which has a 2-aminobenzamide struc...  
WO/2016/040322A1
Described herein are methods of treating tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor;...  
WO/2016/039393A1
The purpose of the present invention is to provide a method for high-yield, inexpensive, and safe industrial production of a lacosamide having high optical purity. The present invention addresses said issue by providing a method for high...  
WO/2016/039462A1
The present invention addresses the problem of providing a method for obtaining Schwann cells directly (by direct reprogramming) without going via pluripotent stem cells such as ES cells, iPS cells or the like. As a means for solving thi...  
WO/2016/038500A1
The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)- benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to t...  
WO/2016/038379A1
The invention relates to pharmaceutical uses of compounds of formula (II). Particular aspects of the invention relate to the use of those compounds in treating, preventing or ameliorating a seizure-related disorder, bipolar disorder, man...  
WO/2016/040643A1
Provided herein are Amyotrophic lateral sclerosis (ALS) biomarkers and methods of using these ALS biomarkers to diagnose and treat ALS.  
WO/2016/039408A1
The present invention addresses the problem of providing a compound that has excellent RORγt-inhibiting effects and is useful as a preventive or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's di...  
WO/2016/038616A1
The present invention provides pharmaceutical compositions comprising at least one NMDA receptor antagonist for use in treating neuropathic forms of Gaucher Disease (nGD).  
WO/2016/037587A1
MitoCells treated with angelica extract is provided. Also provided is a pharmaceutical composition comprising the MitoCells. The pharmaceutical composition can significantly achieve the goal for treating degenerative neurological disease.  
WO/2016/040930A1
The present disclosure is related to methods of treating agitation and/or aggression and/or associated symptoms in subjects with dementia, including, dementia associated with Alzheimer's disease. The method includes administering to a su...  
WO/2016/039163A1
Provided is a hepatocyte growth factor (HGF) preparation such as an injection that is usable for treating central nervous diseases by intramedullary administration, intraventricular administration, administration into spinal parenchyma o...  
WO/2016/039358A1
The present invention pertains to a compound that has an excellent retinoic acid receptor-related orphan receptor γt inhibitory effect, or a pharmaceutically acceptable salt thereof. Provided is a compound represented by general formula...  
WO/2016/039977A1
The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using...  
WO/2016/039448A1
This invention provides a new aromatic carboxylic acid amide compound that has a TRPM8 blocking effect and is useful as a medicine. Specifically, this invention provides an aromatic carboxylic acid amide compound represented by formula (...  
WO/2016/040932A1
Described herein is a novel application involving the use of therapeutic or cosmetic formulations of botulinum toxin involving an increase and enhancement of longevity in human subjects. The inventors are physicians who have used this ag...  
WO/2016/034145A1
A composition of (6S)-5-methyl tetrahydrofolic acid or a salt thereof as well as the preparation therefor and an application thereof. The content of the (6S)-5-methyl tetrahydrofolic acid or the salt thereof is not less than 98.0%, the c...  
WO/2016/035182A1
[Problem] The purpose of the present invention is to provide a composition that is a ginsenoside composition derived from medicinal ginseng and that is particularly useful as a composition for oral use. [Solution] Provided is a compositi...  
WO/2016/035820A1
 Provided are: a centrally-acting peptide derivative having a central action portion, a transmembrane sequence portion, and an endosome escape portion; and a pharmaceutical composition including the same.  
WO/2016/034851A1
Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated...  
WO/2016/037071A3
The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.  
WO/2016/037026A1
Cyclohexylethyl substituted diaza- and triaza-tricyclic compounds, such as e.g. 5-(2-(cyclohexyl)ethyl)-5H-imidazo[5,1-a]isoindole, 1-Cyclohexyl-2-[4,6,10-triazatricyclo[6.4.0.0^[2,6]]dodeca-1 (8),2,4,9,11-pentaen-7-yl]ethan-1-ol derivat...  
WO/2016/036719A1
Provided are methods for slowing, halting, and reversing gray matter atrophy and progression of disability in certain neurodegenerative diseases, including multiple sclerosis using estrogen, alone or in combination with another agent.  
WO/2016/037106A1
The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.  

Matches 101 - 150 out of 110,331